Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Abstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficac...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06089-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863322950238208 |
|---|---|
| author | Satoshi Endo Hisao Imai Atsuto Mouri Kasumi Tsukamoto Kenji Masaki Kosuke Hashimoto Yu Miura Ayako Shiono Ou Yamaguchi Junichi Nakagawa Kyoichi Kaira Kunihiko Kobayashi Hiroshi Kagamu |
| author_facet | Satoshi Endo Hisao Imai Atsuto Mouri Kasumi Tsukamoto Kenji Masaki Kosuke Hashimoto Yu Miura Ayako Shiono Ou Yamaguchi Junichi Nakagawa Kyoichi Kaira Kunihiko Kobayashi Hiroshi Kagamu |
| author_sort | Satoshi Endo |
| collection | DOAJ |
| description | Abstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficacy and safety of first-line Nivo-Ipi therapy in elderly patients with NSCLC. Methods This retrospective study included 57 patients with NSCLC (52 men and 5 women), aged ≥ 75 years (range: 75–86) who received first-line Nivo-Ipi therapy from December 2020 to November 2022 at four institutes in Japan. Patient characteristics, therapeutic efficacy, and the incidence and severity of adverse events (AE) were assessed. Results The overall response rate was 42.1%, the disease control rate was 73.6%, the median progression-free survival (PFS) was 7.1 months, and the median overall survival (OS) was 14.1 months. Common Grade ≥ 3 AEs included pneumonitis, elevated aspartate transaminase, elevated alanine transaminase, adrenal insufficiency, and colitis. No treatment-related deaths were reported. PFS and OS were longer in patients who experienced treatment-related AEs. Patients with and without AEs had a median PFS of 11.7 and 2.8 months, respectively. Similarly, the median OS of patients with and without AEs was 20.4 and 9.0 months, respectively. Conclusion First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatment-related AEs was associated with improved clinical outcomes, suggesting a potential prognostic value of AEs in this population. |
| format | Article |
| id | doaj-art-f7bc7fcf21d84df6988693fe3e7e0492 |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-f7bc7fcf21d84df6988693fe3e7e04922025-02-09T12:10:31ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-01-01151111210.1007/s00432-025-06089-xEfficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancerSatoshi Endo0Hisao Imai1Atsuto Mouri2Kasumi Tsukamoto3Kenji Masaki4Kosuke Hashimoto5Yu Miura6Ayako Shiono7Ou Yamaguchi8Junichi Nakagawa9Kyoichi Kaira10Kunihiko Kobayashi11Hiroshi Kagamu12Division of Respiratory Medicine, Gunma Prefectural Cancer CenterDivision of Respiratory Medicine, Gunma Prefectural Cancer CenterDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDivision of Respiratory Medicine, National Hospital Organization Disaster Medical CenterDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDivision of Respiratory Medicine, National Hospital Organization Takasaki General Medical CenterDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical UniversityAbstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficacy and safety of first-line Nivo-Ipi therapy in elderly patients with NSCLC. Methods This retrospective study included 57 patients with NSCLC (52 men and 5 women), aged ≥ 75 years (range: 75–86) who received first-line Nivo-Ipi therapy from December 2020 to November 2022 at four institutes in Japan. Patient characteristics, therapeutic efficacy, and the incidence and severity of adverse events (AE) were assessed. Results The overall response rate was 42.1%, the disease control rate was 73.6%, the median progression-free survival (PFS) was 7.1 months, and the median overall survival (OS) was 14.1 months. Common Grade ≥ 3 AEs included pneumonitis, elevated aspartate transaminase, elevated alanine transaminase, adrenal insufficiency, and colitis. No treatment-related deaths were reported. PFS and OS were longer in patients who experienced treatment-related AEs. Patients with and without AEs had a median PFS of 11.7 and 2.8 months, respectively. Similarly, the median OS of patients with and without AEs was 20.4 and 9.0 months, respectively. Conclusion First-line Nivo-Ipi therapy is effective in elderly patients with NSCLC. Although there was an increased incidence of pneumonitis, the treatment was manageable and presented as a viable treatment option. Notably, the occurrence of treatment-related AEs was associated with improved clinical outcomes, suggesting a potential prognostic value of AEs in this population.https://doi.org/10.1007/s00432-025-06089-xAdvanced non-small cell lung cancerElderly patientsFirst-line treatmentImmune checkpoint inhibitorIpilimumabNivolumab |
| spellingShingle | Satoshi Endo Hisao Imai Atsuto Mouri Kasumi Tsukamoto Kenji Masaki Kosuke Hashimoto Yu Miura Ayako Shiono Ou Yamaguchi Junichi Nakagawa Kyoichi Kaira Kunihiko Kobayashi Hiroshi Kagamu Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer Journal of Cancer Research and Clinical Oncology Advanced non-small cell lung cancer Elderly patients First-line treatment Immune checkpoint inhibitor Ipilimumab Nivolumab |
| title | Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer |
| title_full | Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer |
| title_fullStr | Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer |
| title_full_unstemmed | Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer |
| title_short | Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer |
| title_sort | efficacy and safety of first line nivolumab plus ipilimumab treatment in elderly patients aged ≥ 75 years with non small cell lung cancer |
| topic | Advanced non-small cell lung cancer Elderly patients First-line treatment Immune checkpoint inhibitor Ipilimumab Nivolumab |
| url | https://doi.org/10.1007/s00432-025-06089-x |
| work_keys_str_mv | AT satoshiendo efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT hisaoimai efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT atsutomouri efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT kasumitsukamoto efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT kenjimasaki efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT kosukehashimoto efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT yumiura efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT ayakoshiono efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT ouyamaguchi efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT junichinakagawa efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT kyoichikaira efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT kunihikokobayashi efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer AT hiroshikagamu efficacyandsafetyoffirstlinenivolumabplusipilimumabtreatmentinelderlypatientsaged75yearswithnonsmallcelllungcancer |